Search Results 1011-1020 of 16374 for monoclonal antibody

1. A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies - Mayo Clinic

   Part 2 (Cohort Expansion): Subjects must have received adequate prior therapy including at a minimum including at a minimum anti-CD20 monoclonal antibody ...

2. Myoclonus - Symptoms and causes - Mayo Clinic

   Hiccups are a form of myoclonus, as are the sudden jerks or "sleep starts" that you may feel just before falling asleep. These forms of myoclonus occur in ...

3. A Study to Evaluate Effectiveness and Safety of MBG453 in Combination with Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia-2 (CMML-2) - Mayo Clinic

   History of severe hypersensitivity reaction to any ingredients of the study treatments (azacitidine or MBG453) or their excipients, or to monoclonal antibodies.

4. A Study Evaluating the Safety and Effectiveness of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) for Adults Hospitalized with Influenza - Mayo Clinic

   The purpose of this study is to test the safety and effectiveness of an antibody ... monoclonal gammopathy); Presence of any pre-existing illness that, in ...

5. Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) - Mayo Clinic

   Previous severe hypersensitivity reaction to another monoclonal antibody (mAb). Active autoimmune disease or a documented history of autoimmune disease or ...

6. A Study to Evaluate IMGN632 with Venetoclax and/or Azacitidine to Treat Patients with CD123-Positive Acute Myeloid Leukemia - Mayo Clinic

   Prior known hypersensitivity reactions to monoclonal antibodies (≥ Grade 3). Prior known hypersensitivity reactions to study drugs and/or any of their ...

7. A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from adverse events due to agents administered more than 4 ...

8. Mayo Clinic Laboratories launches serology testing in support of COVID-19 response

   The serology test is intended only to detect antibodies to the virus, not to diagnose recent or active infection, and it cannot pinpoint the date of exposure.

9. A Phase 2/3 Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma - Mayo Clinic

   Has received prior adjuvant therapy, monoclonal antibody or an investigational agent or device within 4 weeks or 5 half-lives (whichever is longer); Has ...

10. A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma - Mayo Clinic

    Ongoing treatment with other monoclonal antibodies (e.g., infliximab, rituximab), immunomodulators (eg, abatacept, methotrexate, azathioprine, cyclosporine) ...